Seoul National University Hospital
Seoul, 03080, South Korea
NCT Number: NCT03019341
The prevalence of nausea and vomiting after the administration of non-ionic contrast media has rarely been assessed. Thus, the aim of our study is to evaluate the prevalence and risk factors of nausea and vomiting after the exposure to the non-ionic contrast media for computed tomography examinations in adults.
Looking for future studies?
Notify Me20 year and older
All sexes
Observational
Seoul, 03080, South Korea
There is no robust evidence or guideline for fasting prior to contrast-enhanced CT scan in patients. Substantial heterogeneity exists on fasting prior to contrast-enhanced CT worldwide. Through dedicated questionnaires, the investigators plan to prospectively assess the prevalence and the risk factors for nausea and vomiting after the exposure to the non-ionic contrast media agent in adult patients undergoing computed tomography examinations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: For 30 minutes after administration of non-ionic contrast media
Patients will be observed for 30 minutes after the administration of the contrast media agent and medical staffs will record and evaluate the patients' status and the severity of gastrointestinal reaction to the contrast media agent such as nausea or vomiting.
Seoul National University Hospital
Other
Immediate Nausea and Vomiting After the Administration of Non-ionic Contrast Media: Prevalence and Risk Factors
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01895699
Alpha-lipoic Acid, Apoptosis of Endothelial Progenitor Cell
Wuhan, Hubei, China
View Trial DetailsNCT07346131
Contrast Agent, MRI Image Enhancement
Fribourg, Canton of Fribourg, Switzerland
View Trial DetailsNCT02466984
Nausea, Pathological Conditions, Signs and Symptoms
Bordeaux, Aquitaine, France
View Trial DetailsNCT01440465
Cancer, Nausea
Avranches, France
View Trial Details